June 8, 2012

News Release

Company: Olympus Corporation
Representative Director, President: Hiroyuki Sasa
(Code: 7733, First Section, Tokyo Stock Exchange)
Contact: Tetsuo Hyakutake, General Manager, Public Relations and IR Office

Announcement of “Medium-Term Vision”

Olympus Corporation today announced its new Five-Year Medium-Term Vision, for the period starting from the fiscal year ending in March 2013.

Please refer to the attached “Appendix 1” and “Appendix 2” for details.

END
Medium-Term Vision Toward Realization of New Olympus

Regaining credibility through “Back to Basics”
— Rebuilding Olympus and creating new corporate value

Olympus Corporation (hereinafter, “the Company”) is announcing a new medium-term vision for the five years from fiscal year ending March 2013. This vision is based on the new management structure established on April 20, 2012, with “Back to Basics” as the slogan. The Company aims to return to the basic values it had at founding and make a fresh start in order to regain the credibility of its stakeholders, build itself anew, and create new corporate value.

< Corporate Management Policies >

Under the new management structure, we have designated three corporate management policies: “Back to Basics,” “One Olympus,” and “Profitable Growth.” Expressing regret for our past misconduct, we aim to achieve growth with profitability by adopting “Back to Basics” as the principle behind all our actions and strategies. We will make a concerted effort to share values and goals among all our employees around the world with the aim of building “One Olympus.”

• Back to Basics

We aim to regain the credibility of our stakeholders, rebuild Olympus, and create new corporate value by going back to the basic values that existed when Olympus was first established and looking ahead to a fresh start.

(Olympus’ founding basic values)

(i) Our mission to contribute to society and its development through products and solutions.
(ii) Continuously strive to develop the world’s first and best products
(iii) Focus on customers and customer needs.

• One Olympus

We will strive to maximize our corporate value by making a concerted effort to share values and goals among all our employees around the world, harnessing their collective wisdom and demonstrating teamwork.

• Profitable Growth

We will redefine our core business domains as “Medical Business,” “Life Science & Industrial Business” and “Imaging Business.” This will enable us to abandon our previous excessive emphasis on sales, comprehensively review our cost structures and achieve growth with profitability while pursuing efficiency.

< Basic Strategies >

With these management policies as a foundation, we will implement the following basic strategies to rebuild Olympus and create new corporate value.

1. Rebuilding of the Business Portfolio and Optimal Allocation of Management Resources

By designating the “Medical Business,” “Life Science & Industrial Business” and “Imaging Business” as our core business domains, we will invest our management resources strategically with a special focus on the “Medical Business.”
In the Medical Business, we will ensure that expansion of emerging markets, etc. results in increased profitability while securing steady revenue streams by reinforcing the foundation of our gastroenterological endoscope business. In the surgical business, we aim to achieve drastic growth by expanding our market share of the operating room imaging field and by establishing the foundation for an energy business (electrosurgical knives, ultrasound scalpels, etc.) to meet the pressures placed by societal aging, capture the increased demand for minimally invasive therapy and respond to the calls for reduced medical costs.

In the Life Science & Industrial Business, we aim to achieve growth in the industrial business field by proactively enhancing our product lineup utilizing the backbone technologies of the Group and expanding our target markets. In the life science business field, we will carry out drastic earnings structure reform by reducing manufacturing costs through a review of production sites as well as curtailment of SG&A expenses by exerting global control over parts procurement and enhancing operational efficiency.

In the Imaging Business, we will review our product lineup by allocating management resources with a focus on mirrorless interchangeable-lens cameras and high-end compact cameras while improving profitability. In addition, we will strive to achieve profitability in fiscal year ending March 2013 and establish a revenue structure that will enable us to continue generating a steady income stream in the following years. We will do so by enhancing productivity through the restructuring of our existing manufacturing functions, selection and concentration of our advertising expense and reduction of SG&A expenses through personnel optimization.

In our non-business domains, we will reconsider the optimal measures to enhance the value of each business and subsidiary. Specifically, after evaluating their correlation with our business domains and reviewing the best way to improve their value, we will take drastic measures to sell, downscale, liquidate or withdraw from businesses whose continuous operation within the Olympus Group is judged to be difficult from the perspective of profitability and potential. In principle, we will not make new growth investments in non-business domains.

2. Review of Cost Structures

In order to improve the earning capability of the Group, we will significantly reduce COGS and SG&A expenses. Specifically, we will aggressively promote the measures for “personnel optimization,” “reduction in costs through the restructuring of production sites and reinforcement of procurement capability” and “acceleration of Group-wide activities to curtail SG&A expenses.”

With regard to personnel optimization, we will reduce the number of employees by approximately 2,700 (approximately 7% of worldwide employees as of March 31, 2012) by March 31, 2014, by restructuring subsidiaries, global production sites, etc., in addition to enhancing the efficiency of the indirect workforce at headquarters and in each business domain.

As a way to reduce costs through restructuring production sites and reinforcing our procurement capability, we aim to strengthen our cost competitiveness by restructuring—through elimination and consolidation—approximately 40% of the 30 production sites currently operating around the world by fiscal year ending March 2015. Furthermore, we will take measures to curtail procurement costs by controlling the Group’s procurement functions in an integrated manner.

Under the planned group-wide activities to curtail SG&A expenses, we will accelerate the measures that have been promoted since April 2011. Specifically, over the five years up until the fiscal year ending March 2017, we aim to reduce fixed expenses such personnel expenses and lowering the SG&A ratio in our three core business domains (Medical, Life Science & Industrial and Imaging) by approximately 6.6 points, by enhancing the efficiency of our business functions and optimizing personnel.
3. Restoration of Financial Health

We will build up shareholders’ equity through the steady earnings from operations to be secured by implementing our business strategies. Furthermore, we will be focusing growth investment—including R&D and capital expenditures—on the Medical Business in order to improve our investment efficiency, maximize cash flows, and reduce our interest-bearing debt. In addition, we will make efforts to streamline our assets through the prompt disposal of inefficient assets such as unutilized noncurrent assets and reduce our overall inventory so that we can improve our equity ratio to bring stability to management. Finally, we recognize strengthening of capital as an important management matter from the standpoint of strengthening the financial base to support investments in future growth and to enhance the foundations of our business in rebuilding Olympus.

4. Restructuring of Governance

Based on the new corporate governance mechanism that was resolved and approved at the Extraordinary General Meeting of Shareholders held on April 20, 2012, we will manage the Company through the clear segregation of execution and management supervision, which is comprised of highly independent board members. At the same time, to ensure that we never repeat our past errors in which we deferred posting our losses, all Olympus Group employees will make a concerted effort to engage in the restructuring of our corporate governance by expressing integrity in all their actions, making changes in compliance awareness, and strengthening our compliance promotion system.

< Performance Indices and Targets >

Results of implementing these basic strategies will be monitored based on four performance indices, including “return on invested capital (ROIC),” “operating margin,” “free cash flow” and “equity ratio.”

<table>
<thead>
<tr>
<th>(Performance indices)</th>
<th>(Results for FY ended March 2012)</th>
<th>(Targets for FY ending March 2017)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return on invested capital (ROIC)</td>
<td>2.7%</td>
<td>10% or more</td>
</tr>
<tr>
<td>Operating margin</td>
<td>4.2%</td>
<td>10% or more</td>
</tr>
<tr>
<td>Free cash flow</td>
<td>-4.8 billion yen</td>
<td>70 billion yen or more</td>
</tr>
<tr>
<td>Equity ratio</td>
<td>4.6%</td>
<td>30% or more</td>
</tr>
</tbody>
</table>

(Note)

Return on Invested Capital (ROIC)

ROIC is an index that measures income generated on a Company’s invested capital (IC). At Olympus Corporation, ROIC is calculated using the following assumptions:

Return (Operating income after taxes) / IC (Shareholders’ equity + interest-bearing debt)

End

< For more information >

- Media Contact: Public Relations and Investor Relations, Olympus Corporation
### (Consolidated Financial Plans)

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2013</th>
<th>FY/March 2015</th>
<th>FY/March 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>920</td>
<td>1,010</td>
<td>1,160</td>
</tr>
<tr>
<td>Operating income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Operating margin)</td>
<td>50</td>
<td>90</td>
<td>130</td>
</tr>
<tr>
<td>(5%)</td>
<td>(9%)</td>
<td>(11%)</td>
<td></td>
</tr>
<tr>
<td>Ordinary income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Ordinary income ratio)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>21</td>
<td>70</td>
<td>115</td>
</tr>
<tr>
<td>(2%)</td>
<td>(7%)</td>
<td>(10%)</td>
<td></td>
</tr>
<tr>
<td>Net income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(Net income ratio)</td>
<td>7</td>
<td>40</td>
<td>85</td>
</tr>
<tr>
<td>(1%)</td>
<td>(4%)</td>
<td>(7%)</td>
<td></td>
</tr>
<tr>
<td>EBITDA</td>
<td>95</td>
<td>140</td>
<td>185</td>
</tr>
<tr>
<td>(EBITDA margin)</td>
<td>(10%)</td>
<td>(14%)</td>
<td>(16%)</td>
</tr>
</tbody>
</table>

< Assumed foreign exchange rates > US$1 = 80 yen, 1 EUR = 100 yen

### (Business Segment Financial Plans)

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2013</th>
<th>FY/March 2015</th>
<th>FY/March 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td>383</td>
<td>470</td>
<td>570</td>
</tr>
<tr>
<td>Life Science &amp; Industrial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging</td>
<td>149</td>
<td>160</td>
<td>170</td>
</tr>
<tr>
<td>Information and Communication</td>
<td>237</td>
<td>234</td>
<td>245</td>
</tr>
<tr>
<td>Others</td>
<td>54</td>
<td>38</td>
<td>55</td>
</tr>
<tr>
<td>Total</td>
<td>920</td>
<td>1,010</td>
<td>1,160</td>
</tr>
<tr>
<td>Operating income</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Medical</td>
<td>75</td>
<td>97</td>
<td>126</td>
</tr>
<tr>
<td>Life Science &amp; Industrial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Imaging</td>
<td>1</td>
<td>7</td>
<td>9</td>
</tr>
<tr>
<td>Information and Communication</td>
<td>5</td>
<td>5</td>
<td>5</td>
</tr>
<tr>
<td>Others</td>
<td>-6.5</td>
<td>1</td>
<td>5</td>
</tr>
<tr>
<td>Elimination and Corporate</td>
<td>-30</td>
<td>-28</td>
<td>-29</td>
</tr>
<tr>
<td>Total</td>
<td>50</td>
<td>90</td>
<td>130</td>
</tr>
<tr>
<td>Operating margin (%)</td>
<td>5%</td>
<td>9%</td>
<td>11%</td>
</tr>
</tbody>
</table>
Medium-Term Vision Toward Realization of New Olympus

“Back to Basics”

June 8, 2012
Olympus Corporation
Hiroyuki Sasa, President
Overview of Medium-Term Vision

1. Mission for the New Management
2. Recognition of Current Issues
3. Corporate Management Policies
4. Basic Strategies
5. Performance Indices and Targets
6. Key Strategic Measures
7. Financial Plans
1. Mission for the New Management

Endeavor to restore trust, damaged by the series of scandals, to improve corporate value.
2. Recognition of Current Issues

<table>
<thead>
<tr>
<th>Excessive Investment in Non-Business Domain Areas</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ Strategic areas for investment were not clearly identified</td>
</tr>
<tr>
<td>➢ Management system and mechanisms to identify actual conditions in the businesses were insufficient</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Decline in Profitability</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ Response to changes in operating environment was slow</td>
</tr>
<tr>
<td>➢ Management had put too high a priority on the expansion of business scale</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Vulnerable Financial Position</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ Bloated balance sheet</td>
</tr>
<tr>
<td>➢ Significant decrease in net assets</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Insufficient Governance System</th>
</tr>
</thead>
<tbody>
<tr>
<td>➢ Decline of free and vigorous corporate culture</td>
</tr>
<tr>
<td>➢ Insufficient compliance awareness</td>
</tr>
</tbody>
</table>
3. Corporate Management Policy

- Back to Basics
- One Olympus
- Profitable Growth
3. Corporate Management Policy

Back to Basics

◆ Go back to Olympus’ basics and start anew focusing on the future.

Olympus’ Founding Basic Values:
- Our mission to contribute to society and its development through products/solutions
- Continuously strive to develop the world’s first and best products
- Focus on customers and customer needs

◆ Restore the open climate where one can speak out without being censored.
3. Corporate Management Policy

One Olympus

◆ Teamwork
- As one company, overcome the crisis with joined forces

◆ Maximum use of resources to optimize overall operation
- With the same goal in mind, allocate resources efficiently to achieve maximum output as a group

◆ One value, amalgamated strategies
- Share value/goal/strategy among all of Olympus
3. Corporate Management Policy

Profitable Growth

- Redefine and allocate management resources to core business domains
- Abandon extreme sales volume prioritization
- Review cost structure and improve efficiencies to maximize profits
<table>
<thead>
<tr>
<th></th>
<th>Basic Strategies</th>
</tr>
</thead>
<tbody>
<tr>
<td>(i)</td>
<td>Rebuilding of business portfolio/Optimal allocation of management resources</td>
</tr>
<tr>
<td>(ii)</td>
<td>Review of cost structures</td>
</tr>
<tr>
<td>(iii)</td>
<td>Restoration of financial health</td>
</tr>
<tr>
<td>(iv)</td>
<td>Restructuring of governance</td>
</tr>
</tbody>
</table>
4. Basic Strategy

(i) Rebuilding of business portfolio/Optimal allocation of management resources

- By designating “Medical Business,” “Life Science and Industrial Business” and “Imaging Business” as core business domains, we will invest management resources strategically with a special focus on the “Medical Business”

(1) Clarifying our core business domains

<Medical> → Driver of profit & growth
- Reinforce the foundation of the gastroenterological endoscopes business to secure stable profits
- Drastic expansion of Surgical products & emerging market sales

<LIFE/Industrial> → Driver of Opto-Digital Technology & growth
- Apply Opto-Digital Technology to meet the customers’ needs
- Secure profit in Life Science business and expand Industrial business

<Imaging> → Driver of optical/imaging Technology & brand
- Lead Olympus with cutting-edge optical/image technologies and contribute to the company through established brand power
- Establish stable, profit-generating capacity

A company around Medical domain, contributing to the total wellness of people
4. Basic Strategies

(i) Rebuilding of business portfolio/Optimal allocation of management resources

(2) Identification and liquidation of non-business domains

- Reconsideration of optimal measures to improve the value of each business
  - We will withdraw from businesses which we judge to offer insufficient profitability and potential. We will sell, downscale or withdraw from such businesses after evaluating their correlation with core business domains
  - In principle, we will not make new investment in areas other than the core business domains

(3) Establishment of mechanisms to drive optimal allocation of management resources

- Review and strict application of investment appraisal processes
- Periodical review of plans and operating results and thorough implementation of PDCA cycle for management
4. Basic Strategies

(ii) Review of cost structures

(1) Cost reduction
   - Reduction of manufacturing and procurement costs

(2) Significant curtailment of indirect expenses
   - Acceleration of measures toward curtailment of SG&A expenses
   - Streamlining of indirect workforce

Improve profitability of the entire Group through drastic review of cost structures
4. Basic Strategies

(iii) Restoration of financial health

Strive to restore financial health while aiming to maximize shareholders’ value as a basic principle

(1) Securing steady flow of profits from businesses
   • Steady efforts to accumulate shareholders’ equity

(2) Maximization of cash flow
   • By maximizing cash flows generated from businesses, reduce interest-bearing debt

(3) Streamlining of assets
   • Improve efficiency of assets in use
   • Review use of fixed assets and eliminate inefficiencies

Improve equity ratio as soon as possible and realize stable management
(Target: 30% or more by FY/March 2017)
4. Basic Strategies

(iv) Restructuring of governance

(1) Restructuring of governance system
   • Clear segregation of execution and supervision of management
   • Reduce power concentrated in President
     (appointment, compensation committee, etc.)

(2) Reinforcement of internal controls
   • Achieve removal of “Designation as a Security on Alert” within one year through reinforcement of internal controls
   • Establish internal check system
   • Enhance management system for business investments, subsidiaries, and affiliates

(3) Strengthening of the compliance system
   • Develop a system and mechanism to avoid the same mistakes from being made in the future
   • Implement thorough changes in awareness and regain corporate culture which values free spirit and integrity
5. Performance Indices and Targets

(Management Policies)  (Basic Strategies)  (Performance Indices)

Back to Basics

(i) Rebuilding of business portfolio/Optimal allocation of management resources

(ii) Review of cost structures

One Olympus

(iii) Restoration of financial health

Profitable Growth

(iv) Restructuring of governance

Regaining credibility

Return on invested capital (ROIC)

Operating margin

Free cash flow

Equity ratio

Maximization of corporate value

Regaining credibility
## 5. Performance Indices and Targets

<table>
<thead>
<tr>
<th>Performance Indices</th>
<th>Results (FY Ended March 2012)</th>
<th>Target (FY Ending March 2017)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Return on invested capital (ROIC)</td>
<td>2.7%</td>
<td>10% or more</td>
</tr>
<tr>
<td>Operating margin</td>
<td>4.2%</td>
<td>10% or more</td>
</tr>
<tr>
<td>Free cash flow (Cash flow from operating activities + cash flow from investing activities)</td>
<td>-4.8 billion yen</td>
<td>70 billion yen or more</td>
</tr>
<tr>
<td>Equity ratio</td>
<td>4.6%</td>
<td>30% or more</td>
</tr>
</tbody>
</table>
6. Key Strategic Measures

(i) Expansion of Medical Business

(ii) Restructuring of Imaging Business

(iii) Improvement of Life Science business and expansion of Industrial business

(iv) Restructuring of non-business domains

(v) Review of cost structures

(vi) Restoration of financial health

(vii) Restructuring of governance
### 6-(i): Expansion of the Medical Business

**Aim to achieve average annual sales growth of 10% and profit growth of 13%**

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2012 Results</th>
<th>FY/March 2013 Target</th>
<th>FY/March 2015 Target</th>
<th>FY/March 2017 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>349.2 billion yen</td>
<td>383.0 billion yen</td>
<td>470.0 billion yen</td>
<td>570.0 billion yen</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>68.2 billion yen</td>
<td>75.0 billion yen</td>
<td>97.0 billion yen</td>
<td>126.0 billion yen</td>
</tr>
<tr>
<td><strong>Operating margin</strong></td>
<td>20%</td>
<td>20%</td>
<td>21%</td>
<td>22%</td>
</tr>
</tbody>
</table>

**Review of business for the period up to FY/March 2012**

- Measures to provide high added value in “Early Diagnosis” and “Minimally Invasive Therapy” matched market needs.
- Excluding the impact of currency fluctuations, the Medical Business realized sound growth in sales.

**Basic policies for FY/March 2013 and after**

- Reinforcement of the gastroenterological endoscope business
- Realization of drastic growth in the surgical business
- Sales expansion in emerging markets
6-(i): Expansion of the Medical Business

Business Mission and Surrounding Environment

With the aim of realizing a medical environment which cares for the physical and mental health of people around the world by meeting demand for efficiency and delivering effective medical results.

Endoscopes

- Early Diagnosis
- Minimally Invasive Therapy

1. Increasing needs for “Early Diagnosis” and “Minimally Invasive Therapy”
   - Acceleration of aging society + demand for QOL (Quality of Life) from patients + pressure to reduce medical costs
2. A leading comprehensive endoscope manufacturer
   - Continuous provision of innovative devices which meet needs for “Early Diagnosis” and “Minimally Invasive Therapy”
   - Development of medical equipment by pursuing usability
6-(i): Expansion of the Medical Business

Reinforcement of the gastroenterological endoscope business
(Aim to achieve average annual growth of 9%)

- Maintain a commanding market share by introducing new products
  - Introduction and penetration of next-generation endoscopy systems

- Expansion of fields for early diagnosis using endoscopes through the establishment of cutting-edge technologies
  - Measures for standardization of NBI observation as a diagnosis method
  - Definitive diagnosis of lung cancer using an ultrasonic bronchoscope

Image provided by: Dr. Yasushi Sano (National Cancer Center East Hospital)
6-(i): Expansion of the Medical Business

Realization of drastic growth in the surgical business
(Aiming to achieve average annual growth of 14%)

<Tailwinds for early diagnosis using endoscopes and minimally invasive therapy>
Acceleration of aging society + increasing needs for minimally invasive surgeries +
pressure to reduce medical costs

- Gastroenterological Surgery
  /Obstetrics and Gynecology
  Business incubation for the world’s first energy therapeutic instruments using ThunderBeat

- Sales expansion in the urological field leveraging the acquisition of Gyrus ACMI
  From monopolar to bipolar
  From capital-oriented business to disposable business

- Sales expansion in the surgical imaging field leveraging strength in flexible scope technologies
  Flexible scopes: Urology and otorhinology
  ENDOEYLE FLEX
  Laparoscopic Toupet fundoplication (LTF)

- Global expansion of the otorhinological business
  Imaging devices
  Various therapeutic devices

Combine Olympus’technologies and Gyrus ACMI’s sales and marketing capabilities
6-(i): Expansion of the Medical Business

Realization of drastic growth in the surgical business
(Aiming to achieve average annual growth of 14%)

- Acquisition of 25% global share in the operating room imaging field (by 2015)
  - Introduction of new integrated endoscopy video system “VISERA Elite”
  - Expansion of contact points with customers and establishment of business foundation leveraging the penetration of (translumenal) endoscopic surgery and LESS (Laparo-Endoscopic Single-Site) surgery using flexible scopes
  - Enhanced lineup of differentiated products focused on minimally invasive therapeutic techniques

- Establishment of the energy business
  => To grow into a new pillar for the surgical business along with the operating room imaging business

First in the world!

- Market generation through the introduction of sophisticated energy devices
- Expansion of disposal product businesses
- Establishment and utilization of training centers
6-(i): Expansion of the Medical Business

Sales expansion in emerging markets (Aiming to achieve average annual growth of 23%)

- Expand market size and share
  - Increase the number of endoscopic surgeons and reinforce training
    - Shanghai Training Center in 2008
    - Beijing Training Center in 2010
  - Will open and operate 22 training centers in Asia and promote the development of endoscopic surgeons and penetration of endoscopic techniques.

- Cultivate new customer segments by introducing low-end models
  - Strengthen sales and service system
    - China and India

Axeon

*Products to be launched after obtaining legal and regulatory licenses in China*
### 6-(ii): Restructuring of Imaging Business

#### Achieve steady flow of operating income

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2012 Results</th>
<th>FY/March 2013 Target</th>
<th>FY/March 2015 Target</th>
<th>FY/March 2017 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>128.6 billion yen</td>
<td>149.0 billion yen</td>
<td>160.0 billion yen</td>
<td>170.0 billion yen</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>-10.8 billion yen</td>
<td>1.0 billion yen</td>
<td>7.0 billion yen</td>
<td>9.0 billion yen</td>
</tr>
<tr>
<td><strong>Operating margin</strong></td>
<td>-8%</td>
<td>1%</td>
<td>4%</td>
<td>5%</td>
</tr>
</tbody>
</table>

**Review of business for the period up to FY/March 2012**
- Decline in investment efficiency as a result of omni-directional strategies
- High-cost structure for development, manufacturing and sales infrastructures due to sales decrease

**Basic policies for FY/March 2013 and after**
- Focus on mirrorless interchangeable-lens cameras and high-end compact cameras
- Drastic improvement in revenue structure for manufacturing cost and SG&A expenses, etc.
6-(ii): Restructuring of Imaging Business

Focus on mirrorless and high-end compact cameras

Setting realistic growth targets

<table>
<thead>
<tr>
<th>Net sales (Unit: Billion yen)</th>
</tr>
</thead>
</table>

Changes in unit sales (Unit: Million units)

- **SLR (mirrorless and conventional models)**
  - FY Ended March 2012: +180%
  - FY Ending March 2013: +70%
  - FY Ending March 2015: -50%

- **High-end compact cameras**
- **Low-end compact cameras**

Segments to focus on

- **Conventional digital SLR cameras**
- **Mirrorless interchangeable-lens cameras**
- **High-end compact cameras**
- **Low-end compact cameras**

- Highly-profitable growth market
- Top two companies dominate in terms of market share, brand strength and development capability

- Olympus has technological lead in mirrorless cameras

- Highly-profitable stable market
- Differentiation is possible by leveraging Olympus’ advanced optical technologies

- Low-profit mature market (excluding emerging markets)
### 6-(ii): Restructuring of Imaging Business

#### Achieve Profitability in FY/March 2013

<table>
<thead>
<tr>
<th>Measures</th>
<th>Operating income improvement amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact of the floods in Thailand</td>
<td>Control over the impact of the floods in Thailand</td>
</tr>
<tr>
<td>Sales and product domains</td>
<td>Increase in sales of high value added models, Review of product lineup</td>
</tr>
<tr>
<td>Manufacturing field</td>
<td>Decrease manufacturing cost through improvement in plant operations, etc. Decrease manufacturing cost through the reinforcement of collaboration with partners</td>
</tr>
<tr>
<td>R&amp;D field</td>
<td>Review of R&amp;D expenses</td>
</tr>
<tr>
<td>Other SG&amp;A fields</td>
<td>Review and rationalization of IT-related expenses, Review of advertising and brand investment</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>Approx. 12 billion yen</strong></td>
</tr>
</tbody>
</table>
6-(ii): Restructuring of Imaging Business

Extensive product lineup leveraging advanced technologies for mirrorless interchangeable-lens cameras

- Developed differentiated technologies for mirrorless interchangeable-lens cameras ahead of competitors and created markets for these products, launching products equipped with FAST AF, five-axis image stabilizer, etc.

- Will continue to incorporate advanced technologies for differentiation in line with the Technology Road Map in an effort to enhance product lineup as a leading manufacturer of mirrorless interchangeable-lens cameras.
6-(ii): Restructuring of Imaging Business

**Application of advanced technologies developed for mirrorless cameras to high value-added compact cameras**

- Launch of unique high value-added compact cameras
  - Compact cameras for the first time equipped with “ZUIKO”-branded lenses
  - TOUGH will be equipped with FAST AF from mirrorless interchangeable-lens cameras
  - Will launch next-generation flagship models by applying technologies from mirrorless cameras

**Advanced technologies for mirrorless cameras**

- World's fastest FAST AF
- World's first five-axis image stabilizer
- Incubation of markets for mirrorless cameras
- Flagship mirrorless camera
  - OM-D
- High-end compact
  - XZ-1 i ZUIKO DIGITAL lens
  - TG-1 F2.0 high speed lens

**Development of advanced technologies**

- Introduction of advanced technologies
- Unique High value-added compact cameras
6-(ii): Restructuring of Imaging Business

**Drastic improvement in revenue structures**

- Reinforce cost competitiveness by raising manufacturing value-add and enhancing productivity
- Selection and concentration of advertising investment and improvement in SG&A ratio through personnel optimization

<table>
<thead>
<tr>
<th>Key measures</th>
<th>Details of measures</th>
<th>Ratio of cost of sales: Improvement by 3 points (FY/March 2015)</th>
<th>SG&amp;A ratio: Improvement by 8 points (FY/March 2015)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Review of product structure</td>
<td>- Focus on mirrorless interchangeable-lens cameras and high-end compact cameras</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Achieve comprehensive productivity enhancement through the introduction of the latest manufacturing technologies at Shenzhen plant.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Concentrate on the manufacturing of high value-added mirror cell and exchangeable lenses</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Proactive utilization of OEM/EMS for assembly processes</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Restructuring of product functionality</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Maximize effectiveness of SG&amp;A expenses through selection and concentration of advertising investments and re-enhanced online communication with users, etc.</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Optimize the number of employees based in Japan and overseas</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>- Utilize imaging technologies and know-how among employees within the Group</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
6-(iii): Improvement of Revenue in Life Science Business and Expansion of Industrial Business

Aim to achieve average annual sales growth of 5% and profit growth of 21%

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2012 Results</th>
<th>FY/March 2013 Target</th>
<th>FY/March 2015 Target</th>
<th>FY/March 2017 Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Net sales</td>
<td>92.4 billion yen</td>
<td>97.0 billion yen</td>
<td>108.0 billion yen</td>
<td>120.0 billion yen</td>
</tr>
<tr>
<td>Operating income</td>
<td>5.4 billion yen</td>
<td>5.5 billion yen</td>
<td>8.0 billion yen</td>
<td>14.0 billion yen</td>
</tr>
<tr>
<td>Operating margin</td>
<td>6%</td>
<td>6%</td>
<td>7%</td>
<td>12%</td>
</tr>
</tbody>
</table>

Review of business for the period up to FY/March 2012

- War of attrition in a limited market (small product portfolio)
- High cost structure due to inefficient business operations

Basic policies for FY/March 2013 and after

- Proactive product portfolio expansion
- Reform revenue structure
- Increase market share in emerging markets
6-(iii): Improvement of Revenue in Life Science Business and Expansion of Industrial Business

Proactive expansion of product portfolio

- Effectively expand business fields by leveraging the Olympus Group’s global infrastructure from the perspective of customers and technologies/product materials.

<table>
<thead>
<tr>
<th>Customer</th>
<th>Technology/Product material</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Microscopes</td>
</tr>
<tr>
<td></td>
<td>Endoscopes</td>
</tr>
<tr>
<td></td>
<td>Ultrasound</td>
</tr>
<tr>
<td></td>
<td>X-ray analysis</td>
</tr>
</tbody>
</table>

- Development of new business fields through the acquisition of new technologies and product materials
- Development of new customer categories
- Development of new business fields through acquisition of new technologies and product materials

Sales expansion by entering vacant customer category fields
# Improved revenue structures

## Measures

<table>
<thead>
<tr>
<th>Increase profitability with high value-added products</th>
</tr>
</thead>
<tbody>
<tr>
<td>Further customer development in growth markets with the main focus on the Industrial Business</td>
</tr>
<tr>
<td>The Life Science Business will focus on the volume zone which deal with ordinary goods in the advanced research market</td>
</tr>
<tr>
<td>Focus on growing emerging countries and sales expansion</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Reform production structures</th>
</tr>
</thead>
<tbody>
<tr>
<td>Decrease manufacturing costs by reviewing production sites</td>
</tr>
<tr>
<td>✔ Streamlining of overseas production sites (Philippines)</td>
</tr>
<tr>
<td>✔ Streamlining of domestic production sites (Nagano)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Enhance operational efficiency from global perspective</th>
</tr>
</thead>
<tbody>
<tr>
<td>Global control over procurement of parts</td>
</tr>
<tr>
<td>Shared utilization of the Olympus Group’s existing infrastructure</td>
</tr>
<tr>
<td>✔ Manufacturing cost competitiveness developed in the Imaging Business</td>
</tr>
<tr>
<td>✔ Customer management method developed in the Medical Business</td>
</tr>
</tbody>
</table>

## Details of measures

- **Ratio of cost of sales**: Improvement of 1 points (FY/March 2015)
- **SG&A ratio**: Improvement of 2 points (FY/March 2015)
6-(iv): Restructuring of Non Business Domains

—Reconsideration of optimal measures to enhance the value of each business

- We will withdraw from businesses which we judge to offer insufficient profitability and potential. We will sell, downscale or withdraw from such businesses after evaluating their correlation with core business domains.
- In principle, we will not make new investments in areas other than the core business domains.

<table>
<thead>
<tr>
<th>Measures</th>
<th>Details of measures</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dissolution of three domestic</td>
<td>It was resolved to dissolve the following companies at the Board of Directors’ Meeting held on April 27, 2012.</td>
<td>To be sold or liquidated by March 31, 2013</td>
</tr>
<tr>
<td>companies</td>
<td>• Altis Co., Ltd.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• NEWS CHEF Inc.</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Humalabo Co., Ltd.</td>
<td></td>
</tr>
<tr>
<td>Liquidation of subsidiary</td>
<td>It was resolved to liquidate the following company at the Management Implementation Committee Meeting held on March 2, 2012.</td>
<td>To be liquidated by November 30, 2012</td>
</tr>
<tr>
<td></td>
<td>• Olympus Visual Communications Corp.</td>
<td></td>
</tr>
</tbody>
</table>
6-(v): Review of Cost Structures

Measures to reduce SG&A expenses

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2012</th>
<th>FY/March 2015</th>
<th>FY/March 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ratio of SG&amp;A expenses to net sales (Medical + Life Science and Industrial + Imaging + Corporate)</td>
<td>53.2%</td>
<td>48.0%</td>
<td>46.6%</td>
</tr>
</tbody>
</table>

Reduction effect: -6.6pt

- Medical: -0.2pt
- Life Science and Industrial: -1.5pt
- Imaging: -3.1pt
- Corporate: -1.8pt

Total: -6.6pt
6-(v): Review of Cost Structures

Personnel optimization

- Reduction of number of employees by approximately 2,700 (7%) around the world by the March 31, 2014.

- Enhancement of functional efficiency of each business
- Enhancement of efficiency of indirect workforce across the Group
- Enhancement of efficiency through the restructuring of subsidiaries
- Enhancement of efficiency through the restructuring of global production sites
6-(v): Review of Cost Structures

Reduction of costs through the restructuring of production sites and reinforcement of procurement capability

Promotion of Group-wide structural reform of procurement
Restructuring of production sites through the review of product lineup

Procurement
- Restructuring of global supplier structure
- Expansion of bulk purchases mainly for indirect materials

Manufacturing
- Will reduce approximately 40% of 30 sites in the world (FY/March 2015)
  - Will consolidate four sites in Nagano district into one (excluding repair sites)
  - Will close the Philippines plant in 2012, etc.

COGS ratio*
- Improvement by 2 points (FY/March 2015)
- Improvement by 3 points (FY/March 2017)

* Total for Medical, Imaging, Life Science and Industrial, and Corporate
### 6-(vi): Restoration of Financial Health

**Streamlining of assets**
*(Reduction of property, plant and equipment, and operating capital)*

- Expedite the sale of unutilized noncurrent assets
- Promote the shortening of the inventory turnover period through the reduction of inventories

<table>
<thead>
<tr>
<th>Measures</th>
<th>Details of measures</th>
<th>Effect</th>
</tr>
</thead>
<tbody>
<tr>
<td>Reduction of property, plant and equipment</td>
<td>Sale of idle properties</td>
<td>Reduction of 1.5 billion yen (As of March 31, 2014)</td>
</tr>
<tr>
<td>Medical Business</td>
<td>Restructuring and consolidation of expanded product lineup, improvement of supply chain, inventory management method and production method</td>
<td>Shortening by 1.4 months, Reduction by 28 billion yen (As of March 31, 2017)</td>
</tr>
<tr>
<td>Imaging Business</td>
<td>Reduction of production lead time (supply)</td>
<td></td>
</tr>
<tr>
<td>Life Science and Industrial</td>
<td>Improvement of supply chain, inventory management method and production method</td>
<td></td>
</tr>
</tbody>
</table>

**Note:** Effect of asset reduction is based on FY/March 2012 cost of sales
Will use cash flow generated to repay and halve interest-bearing debt
Will reduce the balance of cash and deposits to an adequate level

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2012 Results</th>
<th>FY/March 2017 Five-Year Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Balance of interest-bearing debt at year-end</td>
<td>642.4</td>
<td>300</td>
</tr>
<tr>
<td>Balance of cash and deposits at year-end</td>
<td>200.1</td>
<td>80</td>
</tr>
<tr>
<td>Cash and deposits turnover period (months)</td>
<td>2.9</td>
<td>0.8</td>
</tr>
</tbody>
</table>

Will generate free cash flow amounting to 250 billion yen over five years and halve interest-bearing debt of 350 billion yen through the repayment using free cash flow.

Shorten the cash and deposits turnover period from approximately 3 months to 0.8 months.
6-(vi): Restoration of Financial Health

Resource allocation (R&D, CAPEX, Shareholder return)

- Will continue to invest for growth with a main focus on the Medical Business in order to realize appropriate shareholder returns.

**R&D investment**

<table>
<thead>
<tr>
<th></th>
<th>FY Ending March 2013</th>
<th>FY Ending March 2015</th>
<th>FY Ending March 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>59%</td>
<td>61%</td>
<td>62%</td>
</tr>
<tr>
<td>Imaging</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Life Science and Industrial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The ratio of R&D expenses to consolidated net sales will be maintained at the 7% level.

The composition ratio of the Medical Business will increase by 3 points.

**CAPEX**

<table>
<thead>
<tr>
<th></th>
<th>FY Ending March 2013</th>
<th>FY Ending March 2015</th>
<th>FY Ending March 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>Medical</td>
<td>60%</td>
<td>61%</td>
<td>68%</td>
</tr>
<tr>
<td>Imaging</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Life Science and Industrial</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Others</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

The ratio of CAPEX to consolidated net sales will be maintained at the 3% level.

The composition ratio of the Medical Business will increase by 8 points.
6-(vii): Restructuring of Governance

Restructuring of corporate governance system

- Will shift to a new management system with clear segregation of execution and supervision

(i) Majority of board members consist of highly independent Outside Directors
(ii) Chairman for the Board of Directors served by someone other than President (= Chairman)
(iii) Establishment of the Nominating Committee (To nominate candidates for Chairman, President, Director and Corporate Auditor)
(iv) Establishment of the Compensation Committee (To implement proposals on compensation amount for Directors and compensation standards for Executive Officers)
(v) Maximum length of term for President, maximum length of term for Executive Officers in charge of a particular division (President: six years in principle) and upper age limit will be decided.
Reinforcement of compliance system

Will commence measures toward changes in compliance awareness and reinforcement of promotion system

(i) Establishment of a Compliance Committee chaired by an Outside Director

(ii) Chief Compliance Officer will be appointed and a promotional organization will be established

(ii) Declaration on commitment to compliance by management and enhancement of compliance education for various groups

(iii) Enhancement of the whistle-blowing system and “Compliance Help Line” (external)
6-(vii): Restructuring of Governance

Development of internal control system

- Measures toward the removal of “Designation as a Security on Alert” (Target: within one year)
- Internal project team was established on March 1
- Will establish a Group-wide promotional system with more than 100 staff members in the future

<table>
<thead>
<tr>
<th>March</th>
<th>April</th>
<th>May</th>
<th>June</th>
<th>July</th>
<th>August</th>
<th>September</th>
<th>October</th>
<th>November</th>
<th>December</th>
<th>January</th>
<th>February – May</th>
</tr>
</thead>
</table>

- Internal system development period
- Internal system operational period
- Inspection period

Clarification of improvement measures
- Development of system
- Development of regulations

Implementation of improvement measures

Submission of internal confirmation document
## 7. Financial Plans

- Aim to return to profitability for the FY ending March 2013 and achieve operating income ratio of approximately 11% for the FY ending March 2017 with continuous growth.
- Olympus is sure to achieve this plan in order to regain the credibility of stakeholders and to maximize corporate value.

<table>
<thead>
<tr>
<th></th>
<th>FY/March 2012 Results</th>
<th>FY/March 2013 Plan</th>
<th>FY/March 2015 Three-Year Plan</th>
<th>FY/March 2017 Five-Year Plan</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Net sales</strong></td>
<td>848.5 billion yen</td>
<td>920.0 billion yen</td>
<td>1,010.0 billion yen</td>
<td>1,160.0 billion yen</td>
</tr>
<tr>
<td><strong>Operating income</strong></td>
<td>35.5 billion yen</td>
<td>50.0 billion yen</td>
<td>90.0 billion yen</td>
<td>130.0 billion yen</td>
</tr>
<tr>
<td>(Operating margin)</td>
<td>4%</td>
<td>5%</td>
<td>9%</td>
<td>11%</td>
</tr>
<tr>
<td><strong>Ordinary income</strong></td>
<td>17.9 billion yen</td>
<td>21.0 billion yen</td>
<td>70.0 billion yen</td>
<td>115.0 billion yen</td>
</tr>
<tr>
<td>(Ordinary income ratio)</td>
<td>2%</td>
<td>2%</td>
<td>7%</td>
<td>10%</td>
</tr>
<tr>
<td><strong>Net income</strong></td>
<td>-49.0 billion yen</td>
<td>7.0 billion yen</td>
<td>40.0 billion yen</td>
<td>85.0 billion yen</td>
</tr>
<tr>
<td>(Net income ratio)</td>
<td>-6%</td>
<td>1%</td>
<td>4%</td>
<td>7%</td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>80.3 billion yen</td>
<td>95.0 billion yen</td>
<td>140.0 billion yen</td>
<td>185.0 billion yen</td>
</tr>
<tr>
<td>(Net sales ratio)</td>
<td>9%</td>
<td>10%</td>
<td>14%</td>
<td>16%</td>
</tr>
</tbody>
</table>

[Assumptions for financial plans]
- Exchange rate: US$1 = 80 yen, 1 EUR = 100 yen
Performance forecasts and other forward-looking statements in this presentation reflect judgments and assumptions based on information available at the time of writing. Because of the uncertainty inherent to judgments and assumptions, and because of the potential for future changes in business operations, conditions in Japan or overseas, or other factors, actual results, etc., may differ substantially from the targets stated.